Navigation Links
Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
Date:2/12/2008

- Presentation of Efficacy and Safety Phase III Results -

LAUSANNE, Switzerland, Feb. 12 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, presented today at the 9th International Symposium on GnRH in Berlin, Germany, the results of a phase III study with its new 6-month formulation of Decapeptyl(R)/Trelstar(R) (triptorelin), a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of advanced prostate cancer. These results show similar efficacy and safety to the already marketed 1- and 3-month formulations.

This multicenter, open, non-comparative, phase III study on the efficacy and safety of two consecutive injections of triptorelin 6-month formulation in 120 patients with advanced prostate cancer, showed that 97.5% of patients achieved castrate levels of serum testosterone 28 days after the first injection and that 93% of the patients maintained serum testosterone levels below castrate level (defined as < or equal to 1.735 nmol/L or 50 ng/dL) from week 8 to 48. These efficacy results are similar to those obtained previously with repeated administrations of the 1- and 3-month formulations of triptorelin. Furthermore the adverse event profile of the new 6-month formulation of triptorelin is fully comparable to that observed with the 1- and 3-month formulations.

"Our 1- and 3-month formulations of Decapeptyl(R) and Trelstar(R) are used worldwide in the treatment of prostate cancer. However they require one injection every 4 or 12 weeks respectively. The 6-month formulation will improve patient compliance and increase convenience and comfort with the need of only one intramuscular injection every 24 weeks," said Kamel Besseghir, CEO of Debiopharm S.A.

About Decapeptyl(R)/Trelstar(R)

Triptorelin was licensed-in from Tulane University in 1982. Debiopharm developed and submitted a 1- a
'/>"/>

SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling
2. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
5. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
6. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
7. IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a Phase I/II Clinical Trial in Treatment-Naive HIV-Infected Patients
8. Rapid Growth of Asia-Pacific Clinical Trials Market Focus of New CenterWatch Report
9. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
10. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
11. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...RNewswire-FirstCall/ -- CEL-SCI Corporation,(NYSE:... Material Transfer,Agreement (MTA) with the Nation...d the laboratory of Dr. Francesco M. Marincola, M....to the tumor microenvironment,caused by CEL-SCI,s ...of,the Infectious Disease and Immunogentics Sectio...
(Date:10/7/2008)...Today at ACG Annual Scientific Meeting -, ORLANDO...Pharmaceuticals, Inc. (formerly Microbia, Inc.) an...nounced the presentation of results from a Phase,2...y in 420 patients with,irritable bowel syndrome wi...cates that once- daily oral dosing of linaclotide,...
(Date:10/7/2008)...lighting CIMZIA,s long-term benefits and value in,...ted at American College,of Gastroenterology (ACG),...ata from two studies,presented this week by UCB at...nual Meeting demonstrate that CIMZIA(R) (certolizu...mor Necrosis Factor alpha) - provides,sustained im...
(Date:10/7/2008)...rt Enrolled in Stage A of Trial Assessing Regimen ...and Paclitaxel -, TUSTIN, Calif., Oct. 7 /PRNewsw...(Nasdaq: PPHM ), a clinical stage biopharmaceutic...e treatment of cancer and,hepatitis C virus (HCV) ...nrollment in the first stage of a Phase II trial o...
Breaking Medicine Technology:CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 1deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 2deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 3deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 4deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 5So called sandfish could help materials handling and process technology specialists 5204 1So called sandfish could help materials handling and process technology specialists 5204 2So called sandfish could help materials handling and process technology specialists 5204 3Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 1Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 2Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 3Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 4Isolagen to Present at the JMP Securities Healthcare Focus Conference 8074 1Isolagen to Present at the JMP Securities Healthcare Focus Conference 8074 2
...0, 2007 - Australian,biotechnology company Avexa (... from its Phase IIb trial for apricitabine (ATC).,...ase inhibitor,(NRTI) being developed for the treat...ant HIV., The Phase IIb trial compared the effecti...ts with drug-resistant HIV with,the effectiveness ...
.../ -- Treatment of,coronary artery disease (CAD) ap...ng, according to a study published today in The,Am...on rates for heart attacks (acute myocardial,infar...ossibly due,to broader use of preventive treatment...lines in risk factors like smoking. , The study is...
Other Medicine Technology:Avexa Reports Positive Phase IIb Result 2Avexa Reports Positive Phase IIb Result 3Avexa Reports Positive Phase IIb Result 4Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 2Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 3
(Date:10/7/2008)...RNewswire-FirstCall/ -- Stallergenes S.A.,today an...greement with,Catalent for the promotion and distr...FLEX(R), co-developed and co-manufactured by Catal...sts of a syringe pre-filled with adrenaline, which....3 and 0.15 mg), in an,autoinjector device. The Me...
(Date:10/7/2008)...of asthma in a young child may well be more challe..., according to a review of research and clinical e... Indiana University School of Medicine and Riley H... issue of Clinical Pediatrics . , "Wheezing ca... Professor of Pediatrics at the IU School of Medic...
(Date:10/7/2008)...rial Specialties, Mfg. is pleased to announce the ...hese filters are exclusively available from Indust... push-to-connect style fittings integrated into th...ne filter offers versatility and customization for... (PRWEB) October 7, 2008 -- Exclusively availa...
(Date:10/6/2008)...fight against childhood obesity, researcher notes ... Three-quarters of middle schools have vending mac...new study finds. , The research demonstrates th...ls, and "that those vending machines don,t always ...y Virus, a registered dietitian with the Center fo...
Breaking Medicine News(10 mins):Health News:Stallergenes Partners With Catalent and the Medical House for Commercialization of Adrenaline Autoinjector in Europe 2Health News:Wheezing and asthma in young children 2Health News:Vending Machines Found in Most Middle Schools 2
...ing to recent update, people with type 2 diabetes ...emia) may be able to safely reduce their risk for ...ase niacin.// The finding runs counter to previous... blood sugar levels in diabetics. Certain studies,...
...ing to researchers, low body temperature, low insu...be linked to a slowdown of the aging process. It i...ses the lifespan of animals. Now researchers at th... about slowing down the aging process. They compar...
...ing to a new study, hospitals staffed with more re...- save more lives from deadly complications, and r...ify worries about the nation's growing nursing sho...s because we don't have the knowledge of the regis...
...study contributes to the findings of liver cancer....of Medicine report findings on a potential new tre...archers injected a compound called 3-bromopyruvate...cerous tumor. They say it did not adversely affect...
Other Medicine News:Health News:Nurses save more lives 2
The IDENTI-PRINT II ID system functions as a complete, hospital wide patient identification system. It integrates the benefits of bedside labeling into a multipurpose ID band that consolidates admitt
Volks drive to provide the best optics enables us to bring you a lens with the highest resolution available in a non-contact slit lamp lens. The astonishing detail allows true 3D viewing of the retin
...nting solution that can encode smart labels at the...of the most versatile in the industry! Designed fo...ands and smart labels, the R2844-Z meets the needs...d and more connectivity choices-such as standard s...
The Health Trax System includes real time location services (RTLS), long range active RFID, telemetery and choke-point visibility all in a single intergrated infrastructure. Health Trax Standards-bas
Medicine Products: